X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs GLENMARK PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA GLENMARK PHARMA DISHMAN PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 25.1 12.0 209.3% View Chart
P/BV x 3.3 3.2 105.7% View Chart
Dividend Yield % 0.7 0.4 174.2%  

Financials

 DISHMAN PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
GLENMARK PHARMA
Mar-17
DISHMAN PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs374993 37.7%   
Low Rs129729 17.7%   
Sales per share (Unadj.) Rs197.8325.5 60.8%  
Earnings per share (Unadj.) Rs21.239.3 54.0%  
Cash flow per share (Unadj.) Rs34.748.7 71.4%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.2 342.2%  
Book value per share (Unadj.) Rs179.9159.2 113.0%  
Shares outstanding (eoy) m80.69282.17 28.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.6 48.1%   
Avg P/E ratio x11.921.9 54.1%  
P/CF ratio (eoy) x7.217.7 41.0%  
Price / Book Value ratio x1.45.4 25.9%  
Dividend payout %9.45.1 185.3%   
Avg Mkt Cap Rs m20,306242,991 8.4%   
No. of employees `0000.813.0 6.4%   
Total wages/salary Rs m5,35516,408 32.6%   
Avg. sales/employee Rs Th19,252.77,083.9 271.8%   
Avg. wages/employee Rs Th6,459.51,265.4 510.5%   
Avg. net profit/employee Rs Th2,064.1855.1 241.4%   
INCOME DATA
Net Sales Rs m15,96191,857 17.4%  
Other income Rs m265374 71.0%   
Total revenues Rs m16,22692,230 17.6%   
Gross profit Rs m4,10320,367 20.1%  
Depreciation Rs m1,0912,644 41.3%   
Interest Rs m9442,373 39.8%   
Profit before tax Rs m2,33415,724 14.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m6243,827 16.3%   
Profit after tax Rs m1,71111,088 15.4%  
Gross profit margin %25.722.2 115.9%  
Effective tax rate %26.724.3 109.8%   
Net profit margin %10.712.1 88.8%  
BALANCE SHEET DATA
Current assets Rs m11,01868,746 16.0%   
Current liabilities Rs m9,51727,027 35.2%   
Net working cap to sales %9.445.4 20.7%  
Current ratio x1.22.5 45.5%  
Inventory Days Days11085 130.0%  
Debtors Days Days3596 36.5%  
Net fixed assets Rs m16,30424,132 67.6%   
Share capital Rs m161282 57.2%   
"Free" reserves Rs m12,90744,643 28.9%   
Net worth Rs m14,51644,925 32.3%   
Long term debt Rs m4,18945,363 9.2%   
Total assets Rs m29,805117,639 25.3%  
Interest coverage x3.57.6 45.5%   
Debt to equity ratio x0.31.0 28.6%  
Sales to assets ratio x0.50.8 68.6%   
Return on assets %8.911.4 77.9%  
Return on equity %11.824.7 47.8%  
Return on capital %17.519.1 91.6%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95256,152 8.8%   
Fx outflow Rs m6978,084 8.6%   
Net fx Rs m4,25548,068 8.9%   
CASH FLOW
From Operations Rs m2,7866,574 42.4%  
From Investments Rs m-1,529-7,124 21.5%  
From Financial Activity Rs m-9415,432 -17.3%  
Net Cashflow Rs m3161,992 15.9%  

Share Holding

Indian Promoters % 61.4 48.3 127.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 6.9 53.6%  
FIIs % 12.7 34.4 36.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.5 210.5%  
Shareholders   46,261 56,727 81.6%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  MERCK LTD  NOVARTIS  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Rising Dollar after Fed Minutes; F&O Expiry and Top Stocks in Action Today(Pre-Open)

Indian share markets ended largely flat on Thursday following the expiry of derivative contracts for February series. The S&P BSE Sensex ended down by 25 points.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS